, Tracking Stock Market Picks
Enter Symbol:

up 66.91 %

MEDIVATION INC (MDVN) downgraded to Hold by Needham

Posted on: Monday,  Feb 3, 2014  8:25 AM ET by Needham

Needham rated Hold MEDIVATION INC (NASDAQ: MDVN) on 02/03/2014. Previously Needham rated Buy MEDIVATION INC (NASDAQ: MDVN) on 03/04/2013., when
the stock price was $46.15. Since then, MEDIVATION INC has gained 66.91% as of 02/03/2014's recent price of $77.03.
If you would have followed the previous Needham's recommendation on MDVN, you would have gained 66.91% of your investment in 336 days.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

Needham & Company, LLC focuses on emerging growth companies in technology, biotechnology and life sciences. The firm's research goal is to service the needs of growth-oriented institutional clients. Needham & Company has established itself as a premier specialty investment bank providing timely and valuable analysis on companies that are under-covered by the majority of Wall Street firms.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/3/2014 8:25 AM Hold
as of 10/17/2014
1 Week   
1 Month   
3 Months   
1 YTD up  20.69 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/4/2013 8:25 AM Buy

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy